Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Zai Lab Limited
< Previous
1
2
Next >
Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
August 07, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023
July 20, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients
July 19, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
July 17, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ARGX
ZLAB
Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer
July 14, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis
July 10, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer
July 06, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
June 30, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ARGX
ZLAB
Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China’s NMPA
June 28, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
June 06, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
NVCR
ZLAB
Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting
June 01, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces Participation in June Investor Conferences
May 25, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA
May 18, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates
May 09, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces Strategic Partnership and Global License Agreement with MediLink Therapeutics for a Next Generation Antibody-Drug Conjugate Program in Oncology
April 27, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023
April 20, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting
April 11, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
March 20, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
KRTX
ZLAB
Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates
March 01, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces Participation in March Investor Conferences
February 28, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
February 22, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
February 22, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
February 09, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces Participation in February Investor Conferences
January 31, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
January 30, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
January 18, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab Appoints Michel Vounatsos To Its Board of Directors
January 09, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
January 05, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
NVCR
ZLAB
Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development
January 03, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Tickers
ZLAB
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.